tradingkey.logo

NeuroMetrix Inc

NURO
4.580USD
0.000
Close 12/19, 16:00ETQuotes delayed by 15 min
9.39MMarket Cap
LossP/E TTM

NeuroMetrix Inc

4.580
0.000

More Details of NeuroMetrix Inc Company

NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

NeuroMetrix Inc Info

Ticker SymbolNURO
Company nameNeuroMetrix Inc
IPO dateJul 22, 2004
CEODr. Shai N. Gozani, M.D., Ph.D.
Number of employees13
Security typeOrdinary Share
Fiscal year-endJul 22
Address1000 Winter Street
CityWALTHAM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02451
Phone17818909989
Websitehttps://www.neurometrix.com/
Ticker SymbolNURO
IPO dateJul 22, 2004
CEODr. Shai N. Gozani, M.D., Ph.D.

Company Executives of NeuroMetrix Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Joshua S. Lev
Mr. Joshua S. Lev
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Daniel S. (Dan) Goldberger
Mr. Daniel S. (Dan) Goldberger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joshua S. Lev
Mr. Joshua S. Lev
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Daniel S. (Dan) Goldberger
Mr. Daniel S. (Dan) Goldberger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
2.61M
86.00%
Other Foreign
424.60K
14.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sat, May 10
Updated: Sat, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RS Fund Management LLC
7.28%
Radoff Family Foundation
5.41%
Radoff (Bradley Louis)
4.47%
Fields (Ephraim G)
3.61%
Horowitz (Joshua S)
2.94%
Other
76.29%
Shareholders
Shareholders
Proportion
RS Fund Management LLC
7.28%
Radoff Family Foundation
5.41%
Radoff (Bradley Louis)
4.47%
Fields (Ephraim G)
3.61%
Horowitz (Joshua S)
2.94%
Other
76.29%
Shareholder Types
Shareholders
Proportion
Hedge Fund
7.28%
Individual Investor
3.98%
Investment Advisor
0.02%
Other
88.71%

Institutional Shareholding

Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1
150.00K
7.28%
+150.00K
2024Q4
39
490.33K
24.08%
-26.75K
2024Q3
39
510.19K
26.28%
+122.70K
2024Q2
40
438.06K
22.75%
+75.57K
2024Q1
41
366.36K
19.19%
-4.67K
2023Q4
39
137.59K
12.82%
-4.37K
2023Q3
43
81.42K
7.76%
-83.92K
2023Q2
44
94.20K
9.63%
-83.86K
2023Q1
39
98.47K
10.12%
-78.94K
2022Q4
39
99.34K
10.25%
-74.29K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
RS Fund Management LLC
--
0%
-4.84K
-100.00%
Radoff Family Foundation
--
0%
-111.50K
-100.00%
Radoff (Bradley Louis)
--
0%
-92.00K
-100.00%
Fields (Ephraim G)
--
0%
-65.72K
-100.00%
Horowitz (Joshua S)
--
0%
-29.81K
-100.00%
Mariner Wealth Advisors
--
0%
-10.08K
-100.00%
Geode Capital Management, L.L.C.
--
0%
-12.83K
-100.00%
View more

Related ETFs

Updated: Tue, May 6
Updated: Tue, May 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Nov 20, 2023
Merger
8→1
Nov 20, 2023
Merger
8→1
Nov 20, 2023
Merger
8→1
Nov 20, 2023
Merger
8→1
Date
Type
Ratio
Nov 20, 2023
Merger
8→1
Nov 20, 2023
Merger
8→1
Nov 20, 2023
Merger
8→1
Nov 20, 2023
Merger
8→1

FAQs

Who are the top five shareholders of NeuroMetrix Inc?

The top five shareholders of NeuroMetrix Inc are:
RS Fund Management LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Radoff Family Foundation holds 0.00 shares, accounting for 0.00% of the total shares.
Radoff (Bradley Louis) holds 0.00 shares, accounting for 0.00% of the total shares.
Fields (Ephraim G) holds 0.00 shares, accounting for 0.00% of the total shares.
Horowitz (Joshua S) holds 0.00 shares, accounting for 0.00% of the total shares.

What are the top three shareholder types of NeuroMetrix Inc?

The top three shareholder types of NeuroMetrix Inc are:
RS Fund Management LLC
Radoff Family Foundation
Radoff (Bradley Louis)

How many institutions hold shares of NeuroMetrix Inc (NURO)?

As of 2025Q1, 1 institutions hold shares of NeuroMetrix Inc, with a combined market value of approximately 150.00K, accounting for 7.28% of the total shares. Compared to 2024Q4, institutional shareholding has increased by -16.80%.

What is the biggest source of revenue for NeuroMetrix Inc?

In FY2024, the -- business generated the highest revenue for NeuroMetrix Inc, amounting to -- and accounting for --% of total revenue.
KeyAI